Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Revenue:
Total revenue	$ 865	$ 504
Operating expenses:
Research and development	72,484	76,172
General and administrative	19,296	17,953
Collaboration expense, net	57,509	46,966
Total operating expenses	149,289	141,091
Loss from operations	(148,424)	(140,587)
Other income:
Other income, net	13,537	24,720
Total other income, net	13,537	24,720
Net loss before income taxes	(134,887)	(115,867)
Provision for income taxes	(1,109)	(724)
Net loss	(135,996)	(116,591)
Foreign currency translation adjustment	41	(11)
Unrealized gain (loss) on marketable securities	2,254	(3,454)
Comprehensive loss	$ (133,701)	$ (120,056)
Net loss per common share - basic	$ (1.58)	$ (1.43)
Basic weighted-average common shares outstanding	85,938,720	81,794,630
Net loss per common share - diluted	$ (1.58)	$ (1.43)
Diluted weighted-average common shares outstanding	85,938,720	81,794,630
Collaboration Revenue [Member]
Revenue:
Total revenue	$ 0	$ 0
Grant Revenue [Member]
Revenue:
Total revenue	$ 865	$ 504